Reason for request
Inclusion
Clinical Benefit
| Substantial |
Substantial actual benefit |
Clinical Added Value
| important |
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation. |
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
cyqrVDsx1TE2B9rV
